title: Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis.
abstract: OBJECTIVE
  Fas/FasL is significantly involved in the pathogenesis of rheumatoid arthritis (RA). Fas/FasL gene polymorphism may be associated with susceptibility to rheumatoid arthritis and disease severity.
  
  
  OBJECTIVE
  To investigate the Fas 670 G/A and FasL 843 C/T genotype and allele frequency in patients with RA, and determine its potential association with susceptibility to the disease and the clinical parameters.
  
  
  METHODS
  One hundred and one patients with RA and 105 healthy control subjects were enrolled in the study. Fas 670 A/G and FasL 843C/T genotype polymorphism was investigated by PCR-RFLP. Chi-square test was used for determining the genotype distribution and the allele incidence.
  
  
  RESULTS
  There was no statistically significant difference between the patients with RA and the healthy subjects with respect to Fas-670 A/G and FasL-843C/T genotype distribution and allele frequency (P>0.05). While there was no statistically significant difference in disease severity and various clinical parameters, a correlation was detected between Fas-670 polymorphism and anti-CCP antibody and anemia (P<0.01 and P<0.03, respectively).
  
  
  CONCLUSIONS
  Fas-670A/G and FasL-843C/T promoter gene polymorphisms are not considered to represent a major genetic risk factor for RA susceptibility and disease severity. However, based on these results, Fas-670 promoter polymorphism may modulate anti-CCP antibody synthesis and response in patients with rheumatoid arthritis.
authors.affiliation: Department of Rheumatology, S˛ ifa University, Izmir, Turkey. senolkobak@gmail.com
authors.forename: Ş
authors.initials: Ş
authors.lastname: Kobak
authors.forename: A
authors.initials: A
authors.lastname: Berdeli
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D000740:Anemia / Q000209:etiology / Q000235:genetics; D000918:Antibody Specificity; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000235:genetics* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D053222:Fas Ligand Protein / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D055815:Young Adult; D019014:fas Receptor / Q000235:genetics*
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; C491901:FAS protein, human; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; D019014:fas Receptor